Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Guardant Health

2 abstracts

1 poster

Poster
Poorer outcomes in EGFR L858R-driven NSCLC treated with osimertinib may be addressed with novel combination of BLU-945 and osimertinib
Abstract
Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC).
Org: Mayo Clinic, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, University of Michigan, Duke University Medical Center/Duke Cancer Institute,
Abstract
Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC).
Org: Guardant Health, Inc., Guardant Health, Sarah Cannon Research Institute/Tennessee Oncology, Winship Cancer Institute of Emory University, Massachusetts General Hospital Cancer Center,